Tau LLPS Modulators for Zinc-Driven Phase Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective small molecules that can modulate liquid-liquid phase separation (LLPS) of proteins, which is implicated in neurodegenerative disorders and cancer, as current drug discovery efforts have been limited and face challenges in targeting the complex multivalent interactions driving this process.
Innovation Solution
Development of compounds of Formula (I) and their stereoisomers or pharmaceutically acceptable salts, which are designed to modulate LLPS by integrating chemical moieties that interfere with the chemical grammar of tau protein interactions, including those with zinc, to inhibit phase separation and aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current drug discovery approaches are used to target protein LLPS, then existing drugs can be evaluated, but they fail to effectively modulate LLPS due to the complex multivalent interactions involved
Solution Approach 1:
The patent segments the complex multivalent interaction network into discrete, targetable components by identifying specific protein interfaces and interaction motifs that drive LLPS. The small molecules are designed to bind to these segmented interaction sites, disrupting the overall LLPS process through targeted intervention rather than attempting to modulate the entire complex system at once.
Solution Approach 2:
The patent introduces small molecule compounds as intermediary agents that mediate between the protein interaction partners. These molecules act as molecular mediators that bind to protein interfaces and alter the interaction dynamics, effectively translating the complex protein-protein interactions into controllable small molecule-binding events that can be pharmacologically targeted.
2Reliability
If small molecules are designed to interfere with chemical grammar of protein interactions, then LLPS modulation is achieved, but the chemical tools and drug-like small molecules remain scarce
Solution Approach 1:
The patent systematically varies key molecular parameters including size, shape, functional groups, and binding affinity of small molecule candidates to optimize their ability to modulate LLPS. By changing these parameters and screening for compounds that effectively disrupt protein interactions, the invention expands the library of functional small molecules from scarce to available.
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional elements within single small molecules. These composite compounds integrate hydrophobic regions for protein binding, polar groups for solubility, and specific geometric features for interface compatibility, creating multifunctional molecules that simultaneously achieve multiple desirable properties.
3Adaptability or versatility
If proteins undergo LLPS to form phase-separated droplets, then membraneless compartmentalisation is created for physiological functions, but the high protein concentration promotes aggregation into toxic species
Solution Approach 1:
The patent applies preliminary anti-action by designing small molecules that prevent the transition from functional liquid droplets to toxic aggregates before it occurs. The compounds bind to proteins in their native state and stabilize them against the conformational changes and intermolecular interactions that lead to aggregation, effectively intervening at an early stage to block the harmful pathway while preserving physiological LLPS functions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The designed compounds effectively inhibit zinc-mediated tau LLPS, dissolve phase-separated condensates, and are biocompatible and cell-permeable, offering potential therapeutic benefits for neurodegenerative disorders and cancer.
Implementation Method 1
Liquid-liquid phase separation (LLPS) of proteins and other biomolecules in cells results in the formation of membraneless compartmentalisation
Data Source
AI summary
The present disclosure provides a compound of Formula (I), its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof and a method of preparation of the same. In addition, the present disclosure provides a pharmaceutical composition comprising the compound of Formula (I) and its stereoisomers, intermediates, or pharmaceutically acceptable salt thereof; a pharmaceutically acceptable carrier; and optionally, in combination with one or more other pharmaceutical compositions. Further, the present disclosure provides a method for prevention or treatment of neurodegenerative disease or for treatment of a condition mediated by aggregation of tau, by administering an effective amount of the compound of Formula (I), its stereoisomers, intermediates, pharmaceutically acceptable salt thereof, or the pharmaceutical composition; a pharmaceutically acceptable carrier; and optionally, in combination with one or more other pharmaceutical compositions or with a clinically relevant immune modulator agent.